Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Turner

Nurse Practitioner Waycross, GA Nurse Practitioner

NPI 1720442239 CMS profile 10633104

1720 Old Reynolds St, Waycross, GA 31501

Open in the dashboard

General payments

$2,323

143 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Turner of Waycross, GA is reported in the CMS Open Payments database as having received $2,323 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $208 10
2024 General $405 21
2023 General $502 26
2022 General $470 34
2021 General $739 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Turner
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lauren Turner were reported at $208. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lauren Turner Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $739 $135 $40–$426 $132
2022 $470 $152 $48–$470 $149
2023 $502 $166 $54–$529 $160
2024 $405 $173 $55–$556 $164
2025 $208 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $578 42 payments
  2. AbbVie, Inc. $184 13 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $176 10 payments
  4. Amgen Inc. $167 11 payments
  5. Boston Scientific Corporation $120 4 payments
  6. Astellas Pharma US Inc $90 5 payments
  7. AstraZeneca Pharmaceuticals LP $78 5 payments
  8. GlaxoSmithKline, LLC. $74 5 payments
  9. Galderma Laboratories, L.P. $69 1 payment
  10. Janssen Pharmaceuticals, Inc $66 4 payments
  11. Other $720 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,311 142 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $374 31 payments
  2. Ozempic $360 30 payments
  3. VRAYLAR $172 12 payments
  4. Repatha $151 10 payments
  5. Wegovy $125 6 payments
  6. Otezla $109 7 payments
  7. JARDIANCE $102 6 payments
  8. SYNJARDY $85 5 payments
  9. Saxenda $79 5 payments
  10. XARELTO $66 4 payments
  11. Other $1,389 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

3,118

Median for Nurse Practitioner: 389

Drug cost

$191,829

Median for Nurse Practitioner: $21,885

Branded share of claims

16.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 64 $67,472
Ozempic Semaglutide Brand 31 $25,142
Jardiance Empagliflozin Brand 44 $24,144
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $20,318
Eliquis Apixaban Brand 19 $11,019
Janumet Sitagliptin Phos/Metformin Hcl Brand 18 $10,487
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 12 $3,716
Symbicort Budesonide/Formoterol Fumarate Brand 14 $3,547
Albuterol Sulfate Hfa Albuterol Sulfate Brand 70 $2,115
Pregabalin Generic 44 $1,298

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$22,428

Of which drugs: $60

Medicare patients

97

Average age 74

Services billed

1,092

65 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 38%
Ischemic heart disease 36%
Chronic kidney disease 26%
COPD 25%
Atrial fibrillation 24%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 17 80 $23
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 212 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $86
$86 — —
Korlym
  • Corcept Therapeutics $58
$58 — —
VRAYLAR
  • AbbVie, Inc. $28
$28 — —
Veozah
  • Astellas Pharma US Inc $27
$27 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record